Last reviewed 2026-04-20 · How we verify

NE-58095 DR

At a glance

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

• A Phase II/III, Double-blind, Parallel Group Comparative Study of Oral Administration of NE-58095 Tablets (PHASE2, PHASE3)
• Delayed Release (DR) Risedronate Compared to Immediate Release (IR) in Postmenopausal Women (PHASE2)
• Assess the Influence of a High-fat Meal on the Relative Bioavailability Of Two Formulations of Risedronate (PHASE1)
• Food Effects on the Relative Bioavailability of Different Dosages of Risedronate (PHASE1)
• Study Assessing Dosing Time and Calcium and Vitamin D on the Relative BA of 35 mg DR Risedronate Dosed With Food (PHASE1)
• A Study to Assess the Bioequivalence of Different Formulations of Risedronate in Healthy Male and Female Subjects (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.